Vertex Pharmaceuticals Inc VRTX

What the company does

Vertex Pharmaceuticals Inc is a large-cap company in the Healthcare sector (Biotechnology), with a market value of $132.8B, based in the USA.

It employs about 6,400 people and has been listed since Jul 24, 1991.

Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor.

Cheap or expensive? priced in line with its group

Its price-to-earnings (P/E) is 29.9 versus 36.9 for the median of the Healthcare sector in our universe (25 companies) — priced in line with its group.

Revenue is growing 12% versus the same quarter last year.

On analysts' next-year forecasts the multiple drops to 24.1 — they expect higher earnings.

The average analyst price target is 571.46, 9% above the current price (their view, not ours).

The stock sits at 77% of its one-year range (0% = the low, 100% = the high).

The risks

• • Quarterly report in 8 days (2026-11-02) — a day the stock can move a lot.

Strengths

• ✅ Profitable — 33 of every 100 dollars of revenue stays as profit.
• ✅ Generates free cash flow — profit becomes cash in the bank.
• ✅ Buys back its shares (1% fewer shares in a year).
• ✅ More cash than debt.
• ✅ Most analysts rate it buy (26 vs 1).

What changed this week

Over the past week the stock rose 4.8% (for comparison: S&P 500 -0.4%, sector ETF XLV +1.4%).

This week's news

• Vertex Pharmaceuticals (VRTX) Posts Positive Phase 3 Results For Povetacicept finance.yahoo.com · 2026-10-25
  What the article says

  Vertex Pharmaceuticals (NasdaqGS:VRTX) reported positive Phase 3 results for povetacicept in IgA nephropathy, meeting all key endpoints. The late stage data are set to be published in the New England Journal of Medicine, highlighting the kidney disease program. Vertex plans to pursue FDA accelerated approval for… source ↗

• What Vertex Pharmaceuticals Holders Bought Into finance.yahoo.com · 2026-10-25
  What the article says

  If Vertex Pharmaceuticals was on your watchlist rather than in your portfolio, the return may sting. Investors who held Vertex Pharmaceuticals over the past year are up 24.3%, including dividends. That period included upbeat cystic fibrosis launches, new gene therapy approvals and a planned US$10b move into… source ↗

• How Halozyme, Up Nearly 90% This Year, Is Rivaling Merck And Hitting New Highs finance.yahoo.com · 2026-10-23
  What the article says

  Halozyme makes technologies that allow drugs delivered through intravenous infusion, or IV, to instead be given with under-the-skin shots Continue Reading source ↗

• Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 2026 finance.yahoo.com · 2026-10-23
  What the article says

  - Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept – - Data published in NEJM and presented at ASN highlight povetacicept's unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks… source ↗

• How Halozyme, Up 80% This Year, Is Rivaling Merck And Hitting New Highs finance.yahoo.com · 2026-10-23
  What the article says

  Halozyme makes technologies that allow drugs delivered through intravenous infusion, or IV, to instead be given with under-the-skin shots Continue Reading source ↗

• Gilead Sciences (GILD) vs. AMGN and VRTX: Can Oncology Growth and HIV Strength Drive a New Growth Era Beyond Acquisitions? finance.yahoo.com · 2026-10-22
  What the article says

  Is GILD a good stock to buy? We came across a bullish thesis on Gilead Sciences, Inc. on Astute Optics - US's Substack. In this article, we will summarize the bulls' thesis on GILD. Gilead Sciences, Inc.'s share was trading at $156.51 as of October 20th 2026. GILD's trailing and forward P/E were 17.84 and 15.55… source ↗

What changed since last week

• New risk flag: earnings report coming up.

• The price rose 4.8% since the last summary.